RYTM vs SABS Valuation Comparison 2026 — Intrinsic Value Analysis

Quick Summary — RYTM scores higher on quality with 6.1/10 vs SABS's 5.0/10. RYTM trades at $84.35 while SABS trades at $3.48. Both analyzed daily using SEC EDGAR data across 13 institutional models.

RYTM

Biotechnology

Rhythm Pharmaceuticals, Inc.

Quality

6.1

out of 10

Value Trap

24

SAFE

Price

$84.35

Last close

Models

12/13

Active

VS

SABS

Biotechnology

SAB Biotherapeutics, Inc.

Quality

5.0

out of 10

Value Trap

41

WARN

Price

$3.48

Last close

Models

12/13

Active

RYTM

2 models active

Limited to 2/13 visible models

SABS

Earnings Power Value sees +77.9% upside

Value Trap 41/100 — caution

RYTM vs SABS — Fair Value Comparison

RYTM

SABS

Market Price Model 1 Model 2

Model-by-Model Comparison

Model	Type	RYTM Fair Value	RYTM Upside	SABS Fair Value	SABS Upside
Bayesian DCF	Intrinsic	$23.79	-71.8%	$1.25	-64.1%
Earnings Power Value	Intrinsic	$3.54	-95.7%	$6.17	+77.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

RYTM vs SABS — Which Stock Is More Undervalued in 2026?

RYTM scores higher with a 6.1/10 quality rating vs SABS's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do RYTM and SABS Valuations Compare?

At $84.35, RYTM trades +71.8% above its Bayesian DCF fair value of $23.79, while SABS at $3.48 trades +64.1% above its estimate of $1.25. RYTM shows a wider gap between price and intrinsic value.

Quality of Company: RYTM vs SABS

RYTM earns a Quality of Company score of 6.1/10 compared to SABS's 5.0/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: RYTM vs SABS

RYTM carries a SAFE value trap risk (24/100) while SABS shows WARN risk (41/100). Stocks with value trap scores above 40 may appear undervalued but face deteriorating fundamentals — declining margins, rising debt, or shrinking revenue can make the apparent discount a trap.

Both in Biotechnology

Both RYTM and SABS operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare RYTM vs SABS differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

RYTM

View Full Rhythm Pharmaceuticals, Inc. Analysis →

SABS

View Full SAB Biotherapeutics, Inc. Analysis →

See all Biotechnology stocks →